TD Cowen Increases BioNTech (NASDAQ:BNTX) Price Target to $98.00

BioNTech (NASDAQ:BNTX) had its price target lifted by TD Cowen from $95.00 to $98.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen’s target price indicates a potential upside of 8.73% from the company’s current price.

A number of other analysts have also commented on BNTX. HC Wainwright reissued a “buy” rating and issued a $107.00 target price on shares of BioNTech in a report on Wednesday, April 17th. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. Canaccord Genuity Group restated a “buy” rating and set a $171.00 target price on shares of BioNTech in a research note on Thursday, March 21st. BMO Capital Markets lowered their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, UBS Group decreased their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $118.82.

BioNTech Stock Down 0.8 %

Shares of NASDAQ BNTX opened at $90.13 on Tuesday. The firm’s fifty day moving average is $90.47 and its 200 day moving average is $95.95. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The company has a market cap of $21.43 billion, a price-to-earnings ratio of 21.88 and a beta of 0.25. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, equities research analysts expect that BioNTech will post -1.74 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently made changes to their positions in BNTX. Cary Street Partners Investment Advisory LLC grew its stake in BioNTech by 6.9% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock worth $186,000 after buying an additional 111 shares during the last quarter. Sectoral Asset Management Inc. increased its holdings in shares of BioNTech by 3.5% during the third quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock valued at $374,000 after acquiring an additional 116 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in shares of BioNTech by 2.5% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after acquiring an additional 116 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of BioNTech by 3.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.